It's Going to Be a Big Year for These Pharma Companies

Goldman Sachs Group Inc. sees 2019 as “the year of NASH,” with late stage study results expected from the likes of Intercept Pharmaceuticals Inc., Gilead Sciences Inc., Allergan Plc and Genfit.

Intercept’s Ocaliva should benefit from its first-mover advantage in the blockbuster nonalcoholic steatohepatitis market fueled by rising obesity rates, Goldman analyst Salveen Richter wrote in a note to clients as the American Association for the Study of Liver Diseases conference comes to a close. NASH, an often asymptomatic disease, can lead to cirrhosis or liver cancer.